The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells.

We have examined how the host environment influences the graft-vs-leukemia (GVL) response following transfer of donor T cells to allogeneic chimeras. Donor T cells induce significant GVL when administered in large numbers to established mixed chimeras (MC). However, when using limiting numbers of T cells, we found that late transfer to MC induced less GVL than did early transfer to freshly irradiated allogeneic recipients.

Radiation protocols determine acute graft-versus-host disease incidence after allogeneic bone marrow transplantation in murine models.

Purpose: Effects of radiation sources used for total body irradiation (TBI) on Graft-versus-Host Disease (GvHD) induction were examined.

Materials And Methods: In a T cell receptor (TCR) transgenic mouse model, single fraction TBI was performed with different radiation devices ((60)Cobalt; (137)Cesium; 6 MV linear accelerator), dose rates (0.85; 1.

Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.

Background: Adrenocortical carcinoma (ACC) is a rare tumour, sometimes causing glucocorticoid hypersecretion. Treatment guidelines have not been established, but are currently under investigation.

Case Report: A 55-year-old Caucasian woman presented with adrenal Cushing's disease.

Radiation recall pneumonitis induced by gemcitabine.

Background: Radiation recall pneumonitis describes a very rare reaction in a previously irradiated area of pulmonary tissue after application of pharmacological agents. A case of recall pneumonitis induced by gemcitabine is reported.

Case Report: A 64-year-old female patient with metastasized esophageal carcinoma received simultaneous chemoradiotherapy of the upper mediastinum with 50.

Influence of radiation protocols on graft-vs-host disease incidence after bone-marrow transplantation in experimental models.

Bone-marrow transplantation is an approved curative treatment for many hemato- and oncologic diseases. Nevertheless, the severe acute clinical course of graft-vs-host disease (GVHD) after allogeneic bone-marrow transplantation is frequently fatal, and is to date not curable. Acute GVHD must, therefore, be prevented from the start of the bone-marrow transplantation by immunosuppressive medication, causing sometimes serious side effects.